CDK20抗体;CDK20 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13034(CDK20 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13034(CDK20 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

CDK20 (Cyclin-Dependent Kinase 20), also known as Cell Cycle-Related Kinase (CCRK), is a serine/threonine kinase involved in cell cycle regulation and transcriptional processes. It interacts with cyclins and regulates the activity of RNA polymerase II, impacting gene expression. CDK20 has gained attention due to its overexpression in cancers like hepatocellular carcinoma (HCC), colorectal cancer, and ovarian cancer, where it promotes tumor progression by activating oncogenic pathways such as Wnt/β-catenin. Its role in modulating immune responses and chemoresistance further highlights its therapeutic relevance.

CDK20 antibodies are critical tools for studying its expression, localization, and function in both normal and diseased tissues. These antibodies, often monoclonal or polyclonal, are designed to target specific epitopes of CDK20 and are validated for techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence. They help identify CDK20 as a potential biomarker for cancer diagnosis or prognosis. In therapeutic contexts, CDK20 antibodies may aid in developing targeted inhibitors or antibody-drug conjugates (ADCs). Preclinical studies suggest that blocking CDK20 activity could suppress tumor growth and enhance chemotherapy sensitivity. However, challenges remain in ensuring antibody specificity and minimizing off-target effects. Ongoing research aims to refine CDK20-targeting strategies for clinical translation.